13
Cost
Benefit-Harm
Assessment Policy Level
Moderate Balance of benefits and
harm
Option: Montelukast is an option for
CRSwNP patients either instead of or in
addition to INCS
Low Preponderance of mild
benefit over harm.
Option: Postoperatively in CRSsNP and
CRSwNP patients
Low to High No benefit in light of
potential harm
Recommendation against: CAg may have
anti-bacterial properties in vitro but lacks
efficacy in clinical studies
Low Benefits likely
outweighs harm when
used on a rotating basis
as studied
Option: Topical furosemide aer ESS and
in combination with an INCS may reduce
the recurrence of nasal polyps
Low to
Moderate
(Including
cost of
desensitization)
Clear benefit over harm Recommendation: Aspirin desensitization
should be considered in AERD aer
surgical removal of NPs to prevent
recurrence
